RCS - Avacta Group PLC - Avacta Announces Science Day 2026

AvactaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH5295Za&default-theme=true

RNS Number : 5295Z  Avacta Group PLC  08 April 2026

Avacta Announces 2026 Science Day Event

 

 

LONDON and PHILADELPHIA - April 8, 2026 - Avacta Therapeutics (AIM: AVCT, "the
Company", "Avacta"), a clinical stage biopharmaceutical company developing
pre|CISION(®), a tumor-activated oncology delivery platform, is pleased to
extend an open invitation for colleagues and investors to attend the Company's
2026 Science Day: "The Next Chapter of pre|CISION."

 

The Avacta Science Day event for investors will take place in Central London
on May 6, 2026 commencing at 10.30 AM, at the Royal Society of Chemistry,
Burlington House, Piccadilly, London W1J 0BA.  Avacta team members will share
presentations on the company's scientific achievements and our aspirations, to
be followed by a reception for attendees.

 

Attendance will be limited by the capacity of the venue, so attendees will be
accepted on a first come, first served basis. Investors wishing to attend
should please indicate interest by email at investors@avacta.com
(mailto:investors@avacta.com) .

 

For investors unable to attend in person, the event will be professionally
recorded and the video made available on the Avacta website in due course.

 

 

 

-Ends-

 

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION(®)
platform. pre|CISION(®) is a payload delivery system based on a
tumor-specific protease (Fibroblast Activation Protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Avacta's innovative pre|CISION(®) peptide drug
conjugates (PDC) are a novel entry to the XDC drug class, leveraging the
success of antibody drug conjugates with alternative methods of delivery
beyond antibodies.

 

Our pre|CISION(®) PDCs leverage this tumor-specific release mechanism to
provide unique benefits over traditional antibody drug conjugates, releasing
active payload in the tumor and reducing systemic exposure and toxicity which
enables dosing to be optimized to deliver the best outcomes for patients. The
lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled
pre|CISION(®) version of doxorubicin that delivers the payload directly in
the tumor with limited peripheral blood exposure and has demonstrated
preliminary activity in tumor types sensitive to doxorubicin including
salivary gland cancer and soft tissue sarcoma.

 

About FAP-Exd (AVA6103)

 

AVA6103 is the second clinical candidate and is the first asset in the
pipeline based on the Gen Two innovative pre|CISION(®) sustained release
mechanism that provides for prolonged release of payload directly in the
tumor, minimizing systemic exposure.  AVA6103 is being evaluated in the
FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS).
Preclinical data suggest this approach has optimized payload delivery with a
high intratumoral concentration and prolonged exposure of released payload in
the tumor, coupled with limited systemic exposure to the released payload.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKLXEDFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved